Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Irma Convertino"'
Autor:
Irma Convertino, Massimiliano Cazzato, Silvia Tillati, Sabrina Giometto, Rosa Gini, Giulia Valdiserra, Emiliano Cappello, Sara Ferraro, Marco Bonaso, Claudia Bartolini, Olga Paoletti, Valentina Lorenzoni, Leopoldo Trieste, Matteo Filippi, Giuseppe Turchetti, Michele Cristofano, Corrado Blandizzi, Marta Mosca, Ersilia Lucenteforte, Marco Tuccori
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: The disease activity associated with the drug-utilization patterns of biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) is poorly investigated in real-world studies on rheumatoid arthritis (RA) patients. To investigate the relati
Externí odkaz:
https://doaj.org/article/0dd20fd9428f4f9aaf484373d027b0bb
Publikováno v:
Pharmaceuticals, Vol 16, Iss 12, p 1689 (2023)
The global impact of the COVID-19 pandemic has underscored the pivotal role of drug safety and effective communication within the realm of pharmacovigilance, particularly in times of unprecedented public health emergencies [...]
Externí odkaz:
https://doaj.org/article/712dd96983874616b0765654a99bd449
Autor:
Irma Convertino, Massimiliano Cazzato, Sabrina Giometto, Rosa Gini, Giulia Valdiserra, Emiliano Cappello, Sara Ferraro, Silvia Tillati, Claudia Bartolini, Olga Paoletti, Valentina Lorenzoni, Leopoldo Trieste, Matteo Filippi, Giuseppe Turchetti, Michele Cristofano, Corrado Blandizzi, Marta Mosca, Ersilia Lucenteforte, Marco Tuccori
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Validation of algorithms for selecting patients from healthcare administrative databases (HAD) is recommended. This PATHFINDER study section is aimed at testing algorithms to select rheumatoid arthritis (RA) patients from Tuscan HAD (THAD) a
Externí odkaz:
https://doaj.org/article/c5ed7e6dd95445e2ad6db8ad78374388
Autor:
Irma Convertino, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini, Sabrina Giometto, Claudia Bartolini, Olga Paoletti, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Corrado Blandizzi, Marco Tuccori, Ersilia Lucenteforte
Publikováno v:
Pharmaceuticals, Vol 16, Iss 3, p 465 (2023)
This study is aimed at describing tofacitinib and baricitinib users by characterizing their prescription and healthcare histories, drug and healthcare utilization patterns, and direct costs from a healthcare system perspective. This retrospective coh
Externí odkaz:
https://doaj.org/article/a99c4db821484d31be05aec53e4084f9
Autor:
Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi, Corrado Blandizzi
Publikováno v:
Critical Care, Vol 24, Iss 1, Pp 1-6 (2020)
Abstract Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of
Externí odkaz:
https://doaj.org/article/30b88a3c1ac94c50b62924fc08020826
Autor:
Niccolò Lombardi, Giada Crescioli, Alessandra Bettiol, Marco Tuccori, Annalisa Capuano, Roberto Bonaiuti, Alessandro Mugelli, Mauro Venegoni, Giuseppe Danilo Vighi, Alfredo Vannacci, the MEREAFaPS Study group, Maria Luisa Aiezza, Daria Bettoni, Corrado Blandizzi, Valentina Borsi, Errica Cecchi, Irma Convertino, Martina Del Lungo, Cristina Di Mauro, Gabriella Farina, Sara Ferraro, Annamaria Fucile, Elena Galfrascoli, Elisabetta Geninatti, Linda Giovannetti, Luca Leonardi, Rosa Liccardo, Anna Marra, Eleonora Marrazzo, Giovanna Monina, Silvia Pagani, Maria Parrilli, Concetta Rafaniello, Francesco Rossi, Marco Rossi, Stefania Rostan, Marco Ruocco, Marita Sironi, Giulia Spada, Liberata Sportiello, Giuditta Violetta Vighi
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundAdverse drug event (ADEs) are a significant cause of emergency department (ED) visits and consequent hospitalization. Preventing ADEs and their related ED visits in outpatients remains a public health safety challenge. In this context, the
Externí odkaz:
https://doaj.org/article/9018384e433b4a9bad78df6444709026
Autor:
Marco Tuccori, Sara Ferraro, Irma Convertino, Emiliano Cappello, Giulia Valdiserra, Corrado Blandizzi, Fabrizio Maggi, Daniele Focosi
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy h
Externí odkaz:
https://doaj.org/article/b3069044105e4b988ac7b2c96f288fbb
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Inflammatory bowel diseases (IBDs) are generally not considered a risk factor for the development of lymphoma. When considering IBD treatments, there is good evidence supporting thiopurines (azathioprine, 6-mercaptopurine) as a risk facto
Externí odkaz:
https://doaj.org/article/1f66068b9f2a44efb4038e24469ce63d
Autor:
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Publikováno v:
Expert Opinion on Drug Discovery. 18:231-245
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0ac1e55ef8de5256f36a68ba9ddfbd7
https://doi.org/10.1080/17460441.2023.2170348
https://doi.org/10.1080/17460441.2023.2170348
Autor:
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, Massimo Franchini, Daniele Focosi
Publikováno v:
Expert Opinion on Drug Discovery. 17:531-546
The ongoing COVID19 pandemic represents an unprecedented opportunity to test the feasibility of monoclonal antibody (mAb) therapies against respiratory viruses. While many hurdles were easily predictable (e.g. time to develop, scalability, and econom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc348885056d64ef66583cc02aa8145e
https://doi.org/10.1080/17460441.2022.2058486
https://doi.org/10.1080/17460441.2022.2058486